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The Impact of Sex and Gender on Innovation and Health Technology1  
Dima Elissa, Dr. Neelum Aggarwal, Natalie Ficek, Kyle Mitchell, Sophia Pribus, 
 
Throughout history, there has been an unsettling partiality for men in the healthcare 
industry.  A leading example highlighting this problem is heart disease and the long history of its 
treatment plans directed towards men.  In 1982, a study on cholesterol and its impact on 
cardiovascular disease involved 12,866 men and no women.2  In addition to clinical trials, the 
focus on men was also evident in the area of medical education, where a diverse group of 
diseases, progression, symptomatology and treatments were described with little to no comment 
as to whether sex differences were apparent.3  To this day, the implications of heart disease as 
being a man’s disease are significant, since women continue to be under recognized by health 
professionals when they have symptoms of heart disease.  Since women are less likely to be 
tested for and diagnosed with heart disease due to uncommon symptoms, the available data and 
clinical course data continue to be two areas that are understudied.  In addition to the diagnostic 
problem, the available treatment options continue to be tailored to men and thus are less suitable 
for women.  
In 1993, the National Institutes of Health (NIH) passed the NIH Revitalization Act, 
which ensured the inclusion of women and minorities in clinical research.4  Clinical trials must 
                                                 
1 Adapted from a presentation, The Impact of Gender and Sex on Innovation and Health 
Technology, by Dima Elissa, MBA, CEO and Founder VisMed3D, AMWA Tech and Innovation 
Lead, DI&I Sector and Dr, Neelum Aggarwal, Co-Leader of the Rush University Medical Center 
Alzheimer’s Disease Center Clinical Core and Associate Professor of Neurological Sciences at 
the 2016 Annual Jaharis Symposium, DePaul College of Law (Mar. 15, 2016). 
2 Vidhi Doshi, Why heart disease still considered “man’s disease”?, GENETIC LITERACY 
PROJECT (Nov. 2, 2015), https://geneticliteracyproject.org/2015/11/02/heart-disease-still-
considered-mans-disease/.  
3 Id.  
4 National Institutes of Health Revitalization Act of 1993, S. 1, 103rd Cong. § 492B (a) (1993).  
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include women and minorities unless there is a clear and compelling rationale and justification 
for exclusion.5  For example, excluding women from prostate studies would be an adequate 
rationale, but cost is not an acceptable reason for exclusion.  In addition to including women and 
minorities, researchers must design and carry out trials in a manner that sufficiently provides 
valid analysis based upon the proposed research plan.  The plan and/or proposal must outline the 
composition of the study population and describe why that particular population was chosen.  
Why is Heart Disease a “Man’s Disease”? 
 
 In the 1700s, the heart was linked to emotion, particularly anger.6  In the late nineteenth 
century, William Osler, a physician, challenged this idea by arguing that heart disease was 
caused by stress.7  He identified a typical heart disease patient as a “keen and ambitious man, the 
indicator of whose engine is always ‘full speed ahead.”8  By the 1950s, even though heart disease 
had been linked to diet, exercise, and other physical factors, it was still considered only a man’s 
disease and lifestyle recommendations if made, were directed to at risk men.9 
Fast forward to a 1995 study on aspirin and heart disease.10  Even though the NIH 
Revitalization Act was passed in 1993, which stated that women and minorities must be 
                                                 
5 NIH Policy and Guidelines on The Inclusion of Women and Minorities as Subjects in Clinical 
Research, U.S. DEP’T OF HEALTH & HUMAN SERV. – NAT’L INST. OF HEALTH,  
https://grants.nih.gov/grants/funding/women_min/guidelines_amended_10_2001.htm (last 
visited Jan 6, 2018).  
6 Vidhi Doshi, Why Doctors Still Misunderstand Heart Disease in Women: Reconsidering the 
“typical” heart-attack symptoms, THE ATLANTIC (Oct. 26, 2015), 
http://www.theatlantic.com/health/archive/2015/10/heart-disease-women/412495/#article-
commentsGender Differences.   
7 Id.  
8 Id. 
9 Id. at 3. 
10 Id.  
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represented in clinical trials,11  this study recruited over 22,000 persons, and only involved men.  
Medical illustrations, an important area in medical education and training, also had a 
noticeable male focus.12  Harlan Krumholz, the editor of the New England Journal of Medicine, 
recalled the iconic drawings of Frank Netter, one of the most famous medical illustrators of the 
twentieth century-Netter’s illustrations, and stated there were very few illustrations, that  
depicted a woman with heart disease.”13  
Sex Differences  
 
  A. Structural Differences of the Heart 
 While there are no statistically significant sex-related differences in the heart during 
puberty, there are differences in male and female hearts after puberty. Notably, heart mass is 
fifteen to thirty percent bigger in males than in females14 and thought to be due to myocytes 
undergoing a greater degree of hypertrophy in males compared to females.15  It is unclear 
whether this solely occurs due to the role of sex hormones, particularly estrogen, which provides 
cardio-protection16 or whether genes located on the X chromosomes are expressed at higher 
levels in females than in males.17  In addition, males express genes on the Y chromosome, which 
are clearly not present in females.18  Apart from the genetic contributions, other likely proteins 
                                                 
11 NIH Policy and Guidelines on The Inclusion of Women and Minorities as Subjects in Clinical 
Research, supra note 5.  
12 Id. 
13 Id.  
14 Leslie A. Leinwand, Sex is a potent modifier of the cardiovascular system, 112 THE J. OF 
CLINICAL INVESTIGATION 302, 302 (Aug. 2003), 
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC166308/pdf/JCI0319429.pdf. 
15 Id.  
16 Id. at 304. 
17 Id. at 305. 
18 Id.  
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that may contribute to sex differences in cardiac structure and functioning, include calmodulin-
dependent protein kinase, Akt, glycogen synthase kinase 3B, and myocyte enhancer factor 2 
signaling proteins.19 
Another sex-related difference in the structure of the heart is the anatomic location of 
major vessels.  Even though vessels are composed of the same cell types for both men and 
women, their functions vary.  According to several studies, left ventricular systolic function 
influenced by the anatomic geometry of the left ventricle and left ventricle geometry differs 
between men and women.20  The dual-chambered pump is smaller in women than in men, which 
translates into a smaller stroke volume and thus, a lower cardiac output.21  In addition, the heart 
rate (also known as the rate of pumping) is greater in females than in males, except in utero.22   
One study on atherosclerosis that evaluated age-related left ventricle (LV) remodeling 
found that as patients age, the LV responds differently in its mass and volume between men and 
women.23  According to the results from the  The Multi-Ethnic Study of Atherosclerosis (MESA)  
study, LV mass was found to be increased in men (8.0 g) and decreased in women (-1.6 g) and 
the LV end-diastolic volume decreased for both men (-9.8) and women (-13.3) per decade.24 
There are also differences in the electrical activity of cardiac myocytes.25  Typically, 
                                                 
19 Id.  
20 Virginia H. Huxley, Sex and the cardiovascular system: the intriguing tale of how women and 
men regulate cardiovascular function differently, 31 THE AM. PHYSIOLOGICAL SOC’Y 17, 19 
(Nov. 28 2007), http://www.physiology.org/doi/pdf/10.1152/advan.00099.2006. 
21 Id. at 18.  
22 Id.  
23 John Eng et al., Adverse Left Ventricular Remodeling and Age Assessed with Cardiac MR 
Imaging: The Multi-Ethnic Study of Atherosclerosis, 278 RADIOLOGY 714, 715 (Mar. 2016), 
http://pubs.rsna.org/doi/10.1148/radiol.2015150982. 
24 Id. at 720. 
25 Huxley, supra note 20. 
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women’s electrocardiography (ECG) tests show a longer QT interval after puberty compared to 
men.26   
Even the composition of the blood circulating in the body vary between men and women. 
Females have a lower number of circulating red blood cells per unit volume of plasma, often 
noted as a lower hematocrit.27  The amount of high-density lipoprotein (HDL) is higher and 
triglycerides are lower in females, pre-menopause, than in males and is associated with a lower 
incidence of cardiovascular disease.28  However, after menopause, the lipoprotein profile of 
females becomes more atherogenic and is correlated with the higher incidence of heart disease in 
that population.29  These physiological changes between the sexes is important for clinical 
screening protocols, treatment and clinical trial design and data analyses.  
Sex-related differences also appear during cardiovascular stress.  Generally, men respond 
to cardiovascular stress by increasing vascular resistance, which manifests as an increase in 
blood pressure.30  On the other hand, women respond to stress by increasing their heart rate, 
which increases cardiac output.31  In addition, blood pressure control through the baroflex system 
differs between men and women.32  Men have higher plasma norepinephrine levels than 
women33 and women have reduced sympathetic activity and parasympathetic activity relative to 
men.34  Consequently, women are more vulnerable to orthostatic hypotension and fainting than 
                                                 
26 Id. 
27 Id. 
28 Id. 
29 Id. 
30 Id. at 18. 
31 Id. 
32 Id. 
33 Id. 
34 Id. 
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men due to their body position and fluid shifts.35  Even though the mechanisms underlying sex 
differences are not understood, estrogen and testosterone play a significant role, with testosterone 
in the development of and estrogen in the protection against high blood pressure.36    
B. Sex Differences in the Regulation of Blood Pressure  
 
 According to Reckelhoff, “[m]en are at a greater risk for cardiovascular and renal disease 
than are age-matched, premenopausal women.”37  According to recent studies in which 24-hour 
ambulatory blood pressure monitoring techniques were used, men had higher blood pressure than 
women by about 6–10 mmHg.38  However, after menopause, women had higher blood pressure 
levels than men.39  One possible explanation for this finding is that pre-menopause, estrogen is 
responsible for stimulating nitric oxide production, thereby activating a vasodilator pathway, and 
regulating blood pressures.  At or after menopause, the loss of estrogen can result in the 
dysregulation of this pathway, which subsequently can increase blood pressures.40 
C. Sex Hormones 
 
Sex hormones are also thought to cause the variation in cardiovascular effects between 
men and women.  While premenopausal women have a low incidence of cardiovascular disease 
compared to men, the incidence level rises to the same or even more for women post-
menopause.41  Both androgens and estrogens influence a multitude of vascular biological 
                                                 
35 Id. 
36 Id. at 19-20. 
37 Jane F. Reckelhoff, Gender Differences in the Regulation of Blood Pressure, 37 
HYPERTENSION 1199, 1199 (May 2001), http://hyper.ahajournals.org/content/37/5/1199.full.  
38 Id. 
39 Id. 
40 Id. at 1201.  
41Gorazd Drevensek, The Role of Sex Hormones in the Cardiovascular System, INTECHOPEN at 
31 (Feb. 8, 2012), http://cdn.intechopen.com/pdfs-wm/27778.pdf. See also Cristiana Vitale et al., 
Gender differences in the cardiovascular effects of hormones, 6 FUNDAMENTAL & CLINICAL 
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processes and their cardiovascular effects are multifaceted.”42  Consequently, high androgen 
levels and low estrogens plasma concentrations have been respectively related to the increased 
impact of CVD in men and in postmenopausal women.43 
In addition, risk factors have varying degrees of weight between men and women, 
especially in the presence of an ovarian deficiency state, when the drop in sex hormones 
negatively affects several conditions such as hyperinsulinaemia, obesity, high cholesterol and 
blood pressure.44  After menopause, women develop a pro-atherogenic lipid profile because of 
impaired estrogen production”45 increased tendency for a sedentary lifestyle and both body fat 
distribution and glucose metabolism increase the risk of CVD.  
 In terms of glucose metabolism, while the risk of CVD in both men and women is 
significantly increased in diabetes cases and with an altered glucose metabolism, the probability 
of future cardiovascular events is greater in women with diabetes than in men, especially when 
the disease is associated with increased blood pressure.46  Diabetic women have lower estrogen 
levels than non-diabetic women, and it has been shown to cause a progressive decline in glucose-
stimulated insulin secretion, and to increase insulin resistance by reducing insulin sensitivity.47 
 Some earlier studies showed that hormone replacement therapy (HRT) was beneficial for 
primary cardiovascular prevention.48  Conversely, a post-analysis of the results of the 
                                                 
PHARMACOLOGY 532, 675 (Feb. 22, 2010), http://onlinelibrary.wiley.com/doi/10.1111/j.1472-
8206.2010.00817.x/epdf.  
42 Vitale, supra note 41.  
43 Id. 
44 Id. at 679.  
45 Id.   
46 Id.  
47 Id.  
48 Id. 
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Framingham Study clearly showed that HRT is protective in younger women, but can be harmful 
to those starting treatment late, and especially after the age of sixty.49 
 Estrogen may be beneficial for both genders, but the effect of androgens differs between 
men and women.50  For women, the effect of testosterone depends on background estrogen 
levels, whereas for men, the effect of testosterone depends on its aromatization into estradiol.51 
While androgen replacement in women does not increase cardiovascular risk, replacement 
therapy in men may be beneficial, but long-term interventional studies with physiological 
androgen doses are lacking and therefore warranted.52 
NIH/FDA Guidelines & Funding Changes  
 
 The NIH Revitalization Act of 1993 ensured the inclusion of women and minorities in 
clinical research, which also includes clinical trials.53  In addition, the statute provides that when 
women and minorities are included as subjects, the trial must be designed and carried out in a 
manner sufficient to provide for valid data analysis.54  An issue arises with this provision because 
clinical researchers do not conduct internal analyses stratifying their results between 
men/women, female/male, race routinely or report these data results in the final publication.  
 In May 2014, the NIH took a more focused approach to identify steps to address sex 
differences in preclinical research.55  As part of new policies, the NIH “require[d] applicants to 
                                                 
49 Id. 
50 Id. at 681-82. 
51 Id. at 682.  
52 Id.   
53 National Institutes of Health Revitalization Act of 1993, S. 1, 103rd Cong. § 492B (1993).  
54 Id.  
55 Filling the Gaps: NIH to Enact New Policies to Address Sex Differences, U.S. DEP’T OF 
HEALTH & HUMAN SERV. – NAT’L INST. OF HEALTH OFFICE OF RESEARCH ON WOMEN’S HEALTH, 
(May 14, 2014), https://orwh.od.nih.gov/about/director/messages/nih-policies-sex-differences/.  
 
9 
 
report their cell and animal inclusion plans as part of preclinical experimental design”56 and note 
this in their grant applications.  In theory this policy would promote “a balanced approach to 
addressing male and female differences in cells and animals.”57 
 In June 2015, the NIH took the initiative to include sex as a variable in research by 
announcing some changes to the “instructions for scientists applying for NIH funding” and by 
“revising criteria for the reviewers who judge the funding applications.”58  The NIH highlighted 
“that sex as a biological variable will be factored into research designs, analyses, and reporting in 
vertebrate animal and human studies.”59  Thus, the NIH made sex a fundamental biological 
variable that must be considered in research to ensure both men and women receive full benefits 
from medical research and also guide further research.  Further, “[s]cientists proposing to study 
only one sex will be required to provide strong justification from the scientific literature, 
preliminary data, or other relevant considerations.”60  
 In 2016, a new law mandated that every funding application submitted to the NIH after 
January 1, 2016, would need to describe the research or study proposed in the context of sex and 
gender.61  The reasoning behind this new law was to ensure that research not only gave thought 
about this criteria, but that preclinical research studies include women.  It is problematic to only 
have preclinical studies on one sex or gender, especially with studies that are intended to inform 
understanding of diseases and conditions affecting both sexes.  Failure to account for sex as a 
                                                 
56 Id.  
57 Id.  
58 Studying Sex to Strengthen Science, NAT’L INST. OF HEALTH OFFICE OF RESEARCH ON 
WOMEN’S HEALTH, https://orwh.od.nih.gov/resources/pdf/orwh-igiant-factsheet-studying-sex.pdf.  
59 Id.  
60 Id. 
61 Id. 
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biological variable may undermine the rigor, transparency, and generalizability of research 
findings to the general population.”62 
 The Food and Drug Administration (FDA) Office of Women’s Health (OWH) also has its 
mission aligned to “[a]dvocate for the inclusion of women in clinical trials”63 and therefore, all 
clinical trials must consider sex and gender in order to obtain FDA approval.  As such, the FDA 
outlined an action plan in Section 907 of the FDA Safety and Innovation Act (FDASIA), which 
had the following three overarching priorities to help direct their activities:   
1. Quality: to improve the completeness and quality of demographic subgroup data; 
 2. Participation: to identify barriers to subgroup enrollment in clinical trials and employ 
strategies to encounter greater participation; 
 3. Transparency: to improve the public availability of demographic subgroup data.”64  
In addition to the above priorities, enhancing innovation in the areas of drug and medical devices 
have also been part of the mission of the FDA.65  
A. Impact & Implications 
 
Even with new innovations such as drugs and devices, there still exists an unsettling 
partiality for men in healthcare. 
a. New Innovations 
 
                                                 
62 Including Women and Minorities in Clinical Research, U.S. DEP’T OF HEALTH & HUMAN 
SERV. – NAT’L INST. OF HEALTH OFFICE OF RESEARCH ON WOMEN’S HEALTH, 
https://orwh.od.nih.gov/clinical/women-and-minorities/.  
63Protecting and Advancing Women’s Health, FDA OFFICE OF WOMEN’S HEALTH at i, 
https://www.fda.gov/downloads/scienceresearch/specialtopics/womenshealthresearch/ucm13537
6.pdf.  
64 FDASIA Section 907: Inclusion of Demographic Subgroups in Clinical Trials, FDA, 
https://www.fda.gov/RegulatoryInformation/LawsEnforcedbyFDA/SignificantAmendmentstothe
FDCAct/FDASIA/ucm389100.htm.  
65 Protecting and Advancing Women’s Health, supra note 63.  
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i. Drugs  
 
While the FDA is engaged in both data collection and policy development, it is still 
important to include women in all stages of NIH-sponsored trials.66  These trials can help clarify 
the understanding of diseases, treatment regimens, and care delivery.67  Women make up one of 
the most frequent subgroups of patients for a variety of medical conditions.68  A primary reason 
for the past exclusion of women in clinical trials was the concern of exposing a future fetus to 
experimental drugs.69  While still subject to concern today, this conception was challenged in the 
1990s, when HIV-infected women found themselves ineligible to participate in trials of new 
antiviral therapies.70  This issue was exacerbated by the fact that there were very few alternative 
treatments available.71  The FDA has addressed this issue by formulating steps to facilitate the 
inclusion of premenopausal women into clinical trials.72  To ensure safety, these steps are subject 
to certain exceptions.  In addition to the challenge of treating women before they have reached 
menopause, there lies the even more daunting challenge of treating women who are already 
pregnant.  There remains widespread caution in treating pregnant women with investigational 
                                                 
66 U.S. Senate Comm. – Health, Educ., Labor & Pensions, Democratic Senate and House 
Leaders Request GAO Study on Inclusion of Women in NIH-Supported Clinical Trials (Apr. 30, 
2014), https://www.help.senate.gov/ranking/newsroom/press/democratic-senate-and-house-
leaders-request-gao-study-on-inclusion-of-women-in-nih-supported-clinical-trials. 
67 Id. 
68 Jesse A. Berlin & Susan S. Ellenberg, Inclusion of women in clinical trials, 7 BMC MED. 1, 1 
(Oct. 9, 2009). 
69 Id. at 2. 
70 Id. 
71 Id. See also Haley Gorenberg & Amanda White, Off the Pedestal and into the Arena: Toward 
Including Women in Experimental Protocols, 19(1) REV. LAW SOC. CHANGE 205-46 (1991-92). 
72 Berlin, supra note 68. See also R.B. Merkatz & S.W. Junod, Historical background of changes 
in FDA policy on the study and evaluation of drugs in women, 69 ACAD. MED. J. ASS’N AM. 
MED. COL. 703, 703-07 (Sept. 1994). 
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drugs to protect the developing fetus.73  This leaves pregnant women with very little information 
when making a decision on treatment because there is no past data of the potential effects of 
specific experimental treatments on pregnant women.  
One exception to this are the experimental trials with the H1N1 flu vaccine.74  These 
followed the recommendation of the Center for Disease Control and Prevention and the American 
College of Obstetricians and Gynecologists based on a 2009 study in the Lancet Medical Journal, 
which found that pregnant women were four times more likely to be hospitalized from H1N1 than 
the general population.75  Because pregnant women are considered to be in the high-risk group for 
this infection, the Vaccines and Medications in Pregnancy Surveillance System (VAMPSS) 
conducted a national survey of 1,032 pregnant women who either were or were not vaccinated 
between 2009 and 2012.76  The study concluded that “pregnant women who were vaccinated were 
no more likely to have a miscarriage, a baby born with a birth defect or a baby born smaller than 
normal, compared with a women who did not get a vaccination.”77  
 The issue of the under inclusion of women in clinical studies of experimental drugs was 
addressed in 2001 by the Government Accountability Office (GAO).  The GAO reported that 
although women made up over fifty percent of the study participants for new drug applications, 
                                                 
73 Berlin, supra note 68, at 3.  
74 Id. 
75 Id. See also Annie Gowen, Pregnant Women in D.C. Area Cautious About Swine Flu 
Vaccinations, WASHINGTON POST (Aug. 20, 2009), http://www.washingtonpost.com/wp-
dyn/content/article/2009/08/19/AR2009081903728.html. 
76 Marie Ellis, H1N1 flu: pregnant women can safely take vaccine, MEDICAL NEWS TODAY (Sept. 
24, 2013), https://www.medicalnewstoday.com/articles/266513.php. 
77 Id. 
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only twenty-two percent of early stage clinical trials were made up of women.78  This is cause for 
concern, as phase 1 trials are structured around the assessment of safety and help set initial dosing 
levels.79  This same problem resurfaced in the 2006 and 2007 reviews of clinical trials that were 
done to support the approval of new drugs.80  The review revealed that women were still 
underrepresented in phase 1 trials, compromising approximately only one-third of participants.81  
ii. Devices 
It has been over twenty years since the enactment of the NIH Revitalization Act, and there 
still remains a reluctance to conduct sex-specific analyses and report sex-based differences in 
medical device clinical trials.82  As a result, there remains a dearth of information in regards to 
potential sex differences in dosing, safety, and effectiveness, some of which could have been 
detected in earlier stages of research had females been included.83  In December 2011, the FDA 
issued a draft guidance entitled Evaluation of Sex of Differences in Medical Device Clinical 
Studies, which advocated for an adequate inclusion of women in trials and the reporting of the 
analysis of sex-based differences.84  In its guidance, the FDA stressed the importance of such 
                                                 
78 U.S. Senate Comm. – Health, Educ., Labor & Pensions, supra note 66; see also General 
Accounting Office, Women’s Health: Women Sufficiently Represented in New Drug Testing, but 
FDA Oversight Needs Improvement (July 6, 2001) (GAO-01-754). 
79 Id. 
80 U.S. Senate Comm. – Health, Educ., Labor & Pensions, supra note 66. 
81 Id. 
82 Martha R. Nolan & Thuy-Linh Nguyen, Analysis and Reporting of Sex Differences in Phase 
III Medical Device Clinical Trials – How Are We Doing?, 22 J. WOMEN’S HEALTH 399, 399 
(May 2013). 
83 Id. at 400. 
84 Id. See also Guidance for Industry and FDA Staff, Evaluation of Sex-Specific Data in Medical 
Device Clinical Studies, FDA (Aug. 22, 2014), 
https://www.fda.gov/downloads/MedicalDevices/DeviceRegulationandGuidance/GuidanceDocu
ments/UCM283707.pdf. 
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representation in medical device clinical trials.85  A study of the progression in sex-specific 
analysis and reporting over time was conducted by utilizing the website ClinicalTrials.gov.86  The 
website was chosen because it is one of the fundamental resource for seeking information about 
clinical trials and their study results.87  The results of the search yielded eighty-seven studies with 
a majority (ninety-seven percent) reporting the sex of their participants.88  While the average 
representation of women in device clinical trials was fifty percent, the average rate of female 
participation was categorized by target disease category and was thirty-four percent lower in 
studies on cardiovascular disease than in all other categories.89  A similar study involving 
cardiovascular devices that obtained premarket approval by the FDA was conducted from 2000 to 
2007.  The results concluded that women made up less than one-third of the subject population.90 
It is important to note that although the aforementioned studies demonstrate that women are 
underrepresented as participants in clinical device studies, many of these reviews are not required 
to report sex-specific analysis.91  This reveals not only a persistent pattern of women being 
underrepresented in cardiovascular device trials but also shows a lack of enforcement by the FDA 
in regulating its own reporting directives.92 
A similar study was conducted on the difference between sexes in randomized trials of 
                                                 
85 Nolan, supra note 82. 
86 Id. at 400.  
87 Id. 
88 Id. 
89 Id. 
90 Id. See also S. Sanket Dhruva et al., Gender bias in studies for Food and Drug Administration 
premarket approval of cardiovascular devices, 4 CIRC CARDIOVASC QUAL OUTCOMES 165-71 
(Mar. 2011). 
91 Nolan, supra note 82.  
92 Id. 
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implantable cardioverter-defibrillator (ICD) therapy in high-risk patients.93  The AVID trial was a 
large U.S. study that enrolled patients who had survived cardiac arrest due to ventricular 
fibrillation, syncopal VT, or symptomatic VT94 and yet, in this important study, only twenty-one 
percent of the recruited patients were women.95 
B. NIH Funding Rules/Considerations 
 
The NIH Revitalization Act also has implications on the potential for investments needed 
to conduct certain clinical studies.  In 2014, the NIH invested $10.1 million to assist eighty-two 
grantees in conducting research exploring the effects of sex in preclinical and clinical studies.96 
This program was launched in the fiscal year of 2013 under leadership from the Office of Research 
on Women’s Health.97  The grantees’ projects spanned a wide range of scientific topics including, 
but not limited to (1) basic immunization, (2) cardiovascular physiology, (3) neural circuitry, and 
(4) behavioral health.98  The investment was meant to encourage researchers to study both sexes 
as a fundamental variable in research.99  Including both sexes in clinical studies is important as an 
overreliance on male subjects in preclinical research can obscure key findings related to sex that 
could help guide later studies.100  Discussing the importance of the program, Janine Austin 
Clayton, the NIH Associate Director for Women’s Health Research, remarked: “[t]his funding 
                                                 
93 Yong-Mei Cha et al., Arrhythmias in Women Diagnosis and Management, MAYO CLINIC 
SCIENTIFIC PRESS at 29 (2014). 
94 Id. 
95 Id. 
96 Nat’l Inst. of Health, New supplemental awards apply sex and gender lens to NIH-funded 
research, U.S. DEP’T OF HEALTH & HUMAN SERV. (Sept. 23, 2014), https://www.nih.gov/news-
events/news-releases/new-supplemental-awards-apply-sex-gender-lens-nih-funded-research. 
97 Id. 
98 Id. 
99 Id. 
100 Id. 
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strategy demonstrates our commitment to moving the needle toward better health for all 
Americans, while helping grow our knowledge base for both sexes and building research 
infrastructure to aid future studies.”101  She further stated, “scientists receiving these awards have 
approached their research questions with fresh thinking, and are looking for innovation and 
discovery through a new lens.”102  
C. Evidence-Based Examples of Gender and Sex in Healthcare Treatments  
 
a. Cardiology 
 
There are many known differences between men and women in heart disease, but the 
reason is still unknown, which is a problem.  The 1980s illustrated the complete lack of inclusion 
of women in mainstream medical studies.103  Two of the major cardiovascular studies include (1) 
the Physicians’ Health Study on the effects of aspirin on cardiovascular disease, in which 22,071 
men and zero women physicians were enrolled,104 and (2) the Multiple Risk Factor Intervention 
Trial (MRFIT)—a randomized trial evaluating correlations among blood pressure, smoking, 
cholesterol, and coronary heart disease—in which 12,866 men and zero women were 
participants.105  
                                                 
101 Id. 
102 Nat’l Institutes of Health, New supplemental awards apply sex and gender lens to NIH-
funded research, U.S. DEP’T OF HEALTH & HUMAN SERV. (Sept. 23, 2014), 
https://www.nih.gov/news-events/news-releases/new-supplemental-awards-apply-sex-gender-
lens-nih-funded-research. 
103 Londa Schiebinger, Women’s health and clinical trials, 112 J. CLINICAL INVESTIGATIONS 973, 
973 (Oct. 1, 2003). 
104 Steering Comm. of the Physicians’ Health Study Research Group, Final report on the aspirin 
component of the ongoing Physicians' Health Study, Steering Committee of the Physicians' 
Health Study Research Group, 321 NEW ENG. J. MED. 129 (July 20, 1989). 
105 Multiple Risk Factor Intervention Trial Research Group, Multiple risk factor intervention 
trial: Risk factor changes and mortality results, 248 JAMA 1465 (1982). See also Schiebinger, 
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A more recent study involved a federally funded analysis of MRI scans of the hearts of 
approximately 3,000 male and female adults.106  The MRIs showed a significant difference in the 
way male and female hearts age over time.107  Specifically, as men age, the heart muscle that 
surrounds the main heart chamber grows bigger and thicker.108  In contrast, as women age, the 
same chamber either retains its size or gets smaller.109  Although these results fail to explain the 
cause of the difference between the sexes, they may still illustrate the varying forms of heart failure 
in men and women, which would require sex-specific treatments.110  Doctor John Eng, a lead 
investigator of the study, concluded that a “[t]hicker heart muscle and smaller heart chamber 
volume both portend heightened risk of age-related heart failure, but the gender variations we 
observed mean men and women may develop the disease for different reasons.”111  Because heart 
failure is currently treated by the prescription of medication designed to reduce the thickness of 
the heart muscle over time and because women’s hearts may shrink with age, this treatment method 
is less beneficial to women patients.112 
b. Neuro (degenerative) 
 
Alzheimer’s disease (AD) is a progressive neurodegenerative disorder that 
disproportionately affects women in both prevalence and severity.113  Symptoms include memory 
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loss, cognitive deficits, and behavioral changes.114  Although AD was identified over one-hundred 
years ago, there is still little known about what triggers it.115  Because of this, the current available 
treatments are unable to slow or reverse the damage it causes.116  The chemical nature of AD is 
characterized by the accumulation of two proteins in the brain: amyloid and tau.117  Amyloid 
precursor proteins are divided into smaller amyloid fragments through an unknown process.118 
These fragments accumulate and cause plaque deposits to collect in the extracellular spaces, thus 
disrupting nerve-to-nerve communications and causing fibers to swell as well as other 
morphologic changes.119  Tau is a protein that typically binds and stabilizes components of the 
neurons of the brain.120  In AD, tau accumulation forms neurofibrillary tangles that can disrupt 
important signaling.121  These two processes cause selective neuronal cell death, contributing to 
the disease’s progression.122  
AD’s disproportionate effect on women can stem from the difference in biological 
mechanisms between sexes, including brain anatomy, age-related declines in brain volume, or 
brain glucose metabolism.123  In the United States, approximately 3.4 million women over the age 
of sixty-five are affected by AD compared to 1.8 million men.124  It is speculated that in addition 
to the above-mentioned biological difference, the longevity of women’s lives may play a role.125  
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One study compared global cognitive function to measures of plaque and tangle pathology derived 
from brain autopsies.126  AD pathology was much more likely to be associated with dementia in 
women than men.  Additionally, it was found that women had nearly three times the odds of being 
diagnosed with AD.127  AD pathogeneses may also be affected by a change in metabolisms caused 
by sex hormones.128  Estrogen is known to serve as a brain protectant, and its loss of production 
during menopause may be responsible for deficits in brain metabolism, leading to a higher risk of 
AD.129  With the relationship between gender differences and the onset of AD still ill-defined, it 
is important to gain more knowledge on the interplay between genetic, hormonal, and 
environmental factors.130 
c. Ortho 
 
Women have a higher rate of osteoporosis-related hip fractures than men.131  There are 
many quantitative differences between how men and women develop common musculoskeletal 
disorders.  Anterior cruciate ligament injuries occur two to eight times more frequently in women 
than men.132  Women are five to eight times more likely to suffer an ACL injury than men in high-
intensity sports that require sudden changes in motion.133  Women are twice as likely to sprain 
their ankles than men and are generally more susceptible than men to develop osteoarthritis of the 
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knee.134  Women may be more vulnerable to ligament tears because of the reproductive hormones 
that affect joint laxity.135  When looking at orthopedic ailments in relation to an increase in age, 
women are more likely to develop osteoporosis than men.136  This leads to a higher risk of hip, 
wrist, and vertebral spine fractures.137  
d. Autoimmune 
 
An autoimmune disease is one in which the body produces autoantibodies that attack 
normal healthy cells by mistake.138  While autoimmune diseases affect both men and women, the 
majority (approximately seventy-five percent) are women.139  Specifically, autoimmune diseases 
are one of the leading causes of death and disability in women sixty-five and younger.140  While 
there is not yet an exact reason why women are more susceptible to autoimmune diseases than 
men, there are a few probable theories.141  First, women may be at a higher risk of autoimmune 
diseases because of their more sophisticated immune systems.142  As there is a correlation between 
inflammation and autoimmune disease, the fact that women’s inflammatory responses are stronger 
than men’s leads to a potential for more frequent disease.  Second, women’s hormones may play 
a role in the potential for disease and autoimmune flare ups often associated with hormonal 
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fluctuations.143  Hormonal fluctuations can occur during pregnancy, the menstrual cycle, or when 
using certain contraceptives.144  In addition to these theories, there are a multitude of autoimmune 
diseases that significantly affect women over men.  These include Hashimoto’s thyroiditis, Graves’ 
disease, multiple sclerosis, myasthenia gravis, systemic lupus erythematosus (lupus), and 
rheumatoid arthritis.145  
e. Renal 
 
In the field of nephrology, women seem to be better protected from developing end-stage 
renal disease (ESRD) than men.146  In a community-based screening, it was found that ESRD 
remained low during the reproductive years and began to rise ten years later in women than in 
men.147  Further, the average age when dialysis treatment is started was found to be higher in 
women than in men.148  As kidney function deteriorates with age, the extent of age-related 
glomerular filtration rate (GFR) varies between the sexes.149  Additionally, a recent study with 
more than 200,000 patients receiving dialysis showed that men were more likely than women to 
be on dialysis if they had advanced kidney disease (fifty-nine percent men and forty-one percent 
women).150  This observation does not shed light on underlying reasons or motivation for 
continuing or stopping treatment; however, it illustrates disparities in treatment.  Many of the 
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questions about the sexes and their proportion of ESRD diagnoses remain unanswered; therefore, 
it is imperative to conduct further research on this topic.  
f. Hepatic 
 
Women are more susceptible than men to developing acute liver failure, benign liver 
lesions, primary biliary cirrhosis, and toxin-mediated hepatotoxicity.151  Potential reasons for this 
increased susceptibility may include the effect of sex hormones on oxidative and metabolic 
pathways, differential gene transcriptions in response to injury in women compared with men, and 
sex-based differences in immune regulation.152  Women are more vulnerable than men to the 
negative effects of alcohol and drug use on the liver.  This fact is bolstered by a Denmark study of 
13,000 participants that showed the risk of development of alcohol-related liver disease increased 
in women who consumed between seven to thirteen beverages per week compared to men who 
consumed fourteen to twenty-seven beverages per week.153  Even following the abstinence of 
alcohol, women with alcoholic liver disease have a more rapid progression to fibrosis.154  Several 
factors may contribute to the severity of alcoholic liver disease in women, which include: (1) a 
higher endotoxin level; (2) increased gut permeability to endotoxins; (3) estrogen receptor 
concentrations within the liver; and (4) the potential activation of liver Kupffer cells by estrogen, 
leading to increased inflammation and necrosis.155  
D. Sexual Orientation Reasoning Examples  
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It has been well established by various research projects that health disparities exist among 
the LGBTQIA+ community as a growing minority group.  These biases are primarily rooted in 
bias, stigma, discrimination and other social determinants of health, rather than biological genetics 
or gender identity.  The issues for this population group exist not only within underrepresentation 
in clinical trials, but also in day-to-day healthcare.  These issues can be solved through expansive 
healthcare system changes and education changes, beginning with simple data collection and 
reaching as far as research project formation.  The examples of issues for healthcare correlating to 
the sexual-orientation of patients are plentiful within these areas. 
On a more general scale, the lack of data collection regarding gender identity begins with 
the daily practitioner.  Few clinical practitioners ask about sexual orientation or gender identity 
during general check-ups.  In locations where they do ask, practitioners have noted patient 
reluctance to reveal personal information regarding their sexual orientation.  Conversely, the issue 
of physician discomfort and ignorance on the importance of the information still pervades the 
medical field.156  As an example, discomfort with sharing their sexual identity can keep members 
of the LGBTQIA+ community from seeking preventative healthcare for HIV/AIDS, resulting in 
higher incidence rates in these populations.157  This, of course, only supports negative stereotypes, 
which furthers problems for the community. Until and unless action is taken to educate physicians 
and patients on the importance of disclosing sexual identity information, this discomfort will 
continue to create problems for healthcare development and patient treatment. 
Aside from long-term social problems, failing to collect information on a patient’s sexual 
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orientation can lead to immediate issues for them, such as prolonged delay of treatment or even 
incorrect diagnosis.  One case study shows a fifty-year-old woman who was hospitalized for a high 
fever and severe chills.158  Doctors spent hours trying to determine the source of the issue, and 
eventually discovered that it was an infection in the prostate gland.  If the practitioners had been 
in the practice of collecting information on patients’ sexual orientation, the woman could have 
received a speedier diagnosis and easier treatment.  Similar examples to this exist for transgender 
men as well. 
Many are already working to solve these problems, which (as seen in the examples) stem 
from social stigmas and other social issues, rather than biological problems themselves.  One such 
proposed solution is the invention of Patient Portals, an electronic way for patients to discreetly 
and confidentially enter their personal information from home rather than using verbal answers to 
awkward or embarrassing questions.  The information becomes part of the patient’s medical 
record.159  While solutions like this may aid the problem, the solution lies within education. 
Educating receptionists and physicians at medical centers and throughout clinical trials about the 
importance of such questions can help to provide more effective care for all people, regardless of 
their specified sexual-orientation.160   
E. The Cost of Exclusion 
 
As the reasoning for collecting data on sexual orientation grows, funding agencies have 
become more restrictive of their donations towards clinical trials.  For example, as mentioned in 
previous sections, the NIH has made the inclusion of a diverse group of sex and gender a 
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requirement for funding in many cases, and other federal health research funding organizations 
provide extra subsidies for demonstrated effort to include a wide range of sexual orientations and 
genders in research.161  While such organizations explain that the exclusion of minority groups due 
to excessive cost is not acceptable, concerns about finances for projects are still an issue. 
Recruiting sufficient numbers of participants is difficult enough without considering a balanced 
sex or gender ratio, and oftentimes the inclusion of minorities results in additional costs.162  For 
example, the Society for Women’s Health Research guidelines have advised that research for sex 
differences should use women in different hormonal states,163 which was shown to quadruple the 
medical research grant costs.  While these higher costs upfront can discourage researchers from 
including a more diverse grouping of gender and sexual orientations (as well as other minorities), 
excluding subpopulations can lead to the misapplication of new treatment plans.164  In the long 
run, this will cost even more.  However, it should be noted that there is little data on this subject, 
since the mandated inclusion of a diverse range of sexes and genders is a relatively new concept. 
E. Moving Forward  
 
Although heart disease is sometimes thought of as a “man’s disease,” about the same 
number of women and men die each year of heart disease in the United States.  Despite increases 
in awareness over the past decade, only fifty-four percent of women recognize that heart disease 
                                                 
161 Suzanne Day et al., Essential metrics for assessing sex & gender integration in health 
research proposals involving human participants, 12 PloS One 1, 1 (2017).  
162 Beth A. Brown et al., Challenges of recruitment: focus groups with research study recruiters, 
31 WOMEN & HEALTH 153, 159 (2001). 
163 Marietta Anthony & Mary J. Berg, Biologic and molecular mechanisms for sex differences in 
pharmacokinetics, pharmacodynamics, and pharmacogenetics: Part II, 11 JOURNAL OF 
WOMEN'S HEALTH & GENDER-BASED MED. 617, 619 (2002). 
164 Joy Johnson, Sex, gender and clinical research: have you considered the possibilities?, 5 
Clinical Investigations 1 (2015).  
 
26 
 
is also a woman’s number one killer.165  While chest pain is the most common symptom of a 
heart attack, women can have symptoms that are not related to chest pain.  Some of these subtle 
symptoms include unusual fatigue: sweating; shortness of breath; and neck, jaw, or back pain.166  
These subtle symptoms often make it more difficult for women to recognize that they are 
experiencing a heart attack, and therefore, women are less likely than men to go to the 
emergency room after a heart attack.  There needs to be more awareness of the differences 
between women and men relating to the presentation of angina pectoris and ACS.  Studies and 
guidelines should also consider sex-related differences when studying heart disease symptoms.  
Healthcare professionals and researchers must include women in studies so that they can better 
understand the biological differences between men and women that affect how they should be 
treated.  
Research on sex and gender differences in clinical and basic science research must 
increase in the United States.  Despite progress, many science researchers do not explore the 
impact of sex on disease.  Many studies simply do not include women or enough women to 
analyze sex-based differences.167  The lack of inclusion of both sexes and analyses of the data 
based on potential sex differences in all clinical and basic science research has far reaching 
implications.  The economic costs of not diagnosing, treating or administering the appropriate 
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drugs and treatment, will continue  to negatively impact utilization costs, development of 
effective and appropriate treatment plans and limit specific and targeted drug discovery and 
research initiatives.  
G. AMWA Chicago Accelerator  
 As established by the previous sections, serious changes must be made to the systems of 
healthcare innovation in order to support a broader spectrum of individuals.  While these changes 
must ultimately be made on a larger scale, independent accelerators have the potential to change 
the way minorities are included in clinical trials.  More importantly, they have the potential to 
begin a revolution that will ultimately result in safer, better, and pioneering solutions in 
healthcare for all people. 
 In general, an accelerator is meant to supply new innovation and grow companies with 
support.  In the healthcare industry, this means providing the resources necessary to succeed and 
eventually spur innovation.  These accelerators exist around the country and focus on various 
sectors of healthcare.168  For example, Dreamit Health based in New York and Philadelphia aims 
to help founders of companies find customers, perfect their marketing strategies, and raise 
funding.  They offer programs to initiate new companies, and ultimately help them with the 
technology and development side of their ideas.169  Another example is MATTER based in 
Chicago, which serves as an incubator for healthcare innovators.  They help healthcare start-ups 
by providing a healthcare and technology experts, access to important connections, and as a 
whole, to accelerate the development of revolutionary healthcare technologies.170  Some 
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accelerators work to specifically support minority groupings, such as women.  Accelerators like 
Avindé in Austin171 or The Brandery in Cincinnati support female founders for companies 
through connection-based or financial methods.172  
Few accelerators, however, focus on helping companies that seek to solve the sex and  
gender bias in healthcare development.  As this article has discussed, the inclusion of sex and 
gender into clinical trial is incredibly important for developing beneficial healthcare for all 
people.  This is the goal of AMWAxcel, (AMWAxcel.com), an accelerator spearheaded by Dima 
Elissa, MBA and Dr. Neelum Aggarwal under the American Medical Women’s Association 
Diversity, Inclusion and Innovation Sector focusing on creating an environment for diversity and 
inclusion in the spectrum of innovation.173  Groups like this are essential to overcome both 
historical and existing biases in medical development.  Through teamwork and collaboration of 
Women-in-STEM accelerators across the globe, these biases can be replaced with a new era of 
inclusive healthcare.  
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